These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 2944913)

  • 21. Endocrine dysfunction in Prader-Willi syndrome: a review with special reference to GH.
    Burman P; Ritzén EM; Lindgren AC
    Endocr Rev; 2001 Dec; 22(6):787-99. PubMed ID: 11739333
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Appetite hormones and the transition to hyperphagia in children with Prader-Willi syndrome.
    Goldstone AP; Holland AJ; Butler JV; Whittington JE
    Int J Obes (Lond); 2012 Dec; 36(12):1564-70. PubMed ID: 22270375
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of a tricyclic antidepressant and opiate antagonist on binge-eating behavior in normoweight bulimic and obese, binge-eating subjects.
    Alger SA; Schwalberg MD; Bigaouette JM; Michalek AV; Howard LJ
    Am J Clin Nutr; 1991 Apr; 53(4):865-71. PubMed ID: 2008865
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of naloxone on hyperphagia in Prader-Willi syndrome.
    Kyriakides M; Silverstone T; Jeffcoate W; Laurance B
    Lancet; 1980 Apr; 1(8173):876-7. PubMed ID: 6103230
    [No Abstract]   [Full Text] [Related]  

  • 25. Randomised crossover trial of naltrexone in uraemic pruritus.
    Peer G; Kivity S; Agami O; Fireman E; Silverberg D; Blum M; laina A
    Lancet; 1996 Dec; 348(9041):1552-4. PubMed ID: 8950882
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of topiramate in adults with Prader-Willi syndrome.
    Shapira NA; Lessig MC; Lewis MH; Goodman WK; Driscoll DJ
    Am J Ment Retard; 2004 Jul; 109(4):301-9. PubMed ID: 15176917
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A preliminary study of beta endorphin during chronic naltrexone maintenance treatment in ex-opiate addicts.
    Kosten TR; Kreek MJ; Ragunath J; Kleber HD
    Life Sci; 1986 Jul; 39(1):55-9. PubMed ID: 2941636
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [A teenager with Prader-Willi syndrome with loss of appetite].
    Smorenberg A; Buter NH; Mollema R; Toornvliet AC; Hack WW
    Ned Tijdschr Geneeskd; 2014; 158():A7503. PubMed ID: 25096033
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Voluntary alcohol consumption and plasma beta-endorphin levels in alcohol-preferring rats chronically treated with naltrexone.
    Zalewska-Kaszubska J; Gorska D; Dyr W; Czarnecka E
    Physiol Behav; 2008 Mar; 93(4-5):1005-10. PubMed ID: 18262210
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combining ondansetron and naltrexone effectively treats biologically predisposed alcoholics: from hypotheses to preliminary clinical evidence.
    Johnson BA; Ait-Daoud N; Prihoda TJ
    Alcohol Clin Exp Res; 2000 May; 24(5):737-42. PubMed ID: 10832917
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cerebral beta-endorphin levels in a woman with Prader-Labhart-Willi syndrome.
    Pasi A; Mehraein P; Gramsch C; Jehle A; Briner J; Häni M; Külling P; Hauri R; Messiha FS
    Physiol Behav; 1989 Jul; 46(1):17-8. PubMed ID: 2530599
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Temper outbursts in Prader-Willi syndrome: causes, behavioural and emotional sequence and responses by carers.
    Tunnicliffe P; Woodcock K; Bull L; Oliver C; Penhallow J
    J Intellect Disabil Res; 2014 Feb; 58(2):134-50. PubMed ID: 23374136
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Using stable isotopes to assess reduced physical activity of individuals with Prader-Willi syndrome.
    Davies PS; Joughin C
    Am J Ment Retard; 1993 Nov; 98(3):349-53. PubMed ID: 8292311
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The efficacy and safety of long-term Norditropin® treatment in children with Prader-Willi syndrome.
    Meinhardt U; Christiansen JS; Farholt S; Lämmer C; Ostergaard JR; Schmidt F; Kappelgaard AM; Eiholzer U
    Horm Metab Res; 2013 Jul; 45(7):532-6. PubMed ID: 23632904
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Linear growth response to exogenous growth hormone in Prader-Willi syndrome.
    Lee PD; Wilson DM; Rountree L; Hintz RL; Rosenfeld RG
    Am J Med Genet; 1987 Dec; 28(4):865-71. PubMed ID: 3688024
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A controlled trial of naltrexone in obese humans.
    Malcolm R; O'Neil PM; Sexauer JD; Riddle FE; Currey HS; Counts C
    Int J Obes; 1985; 9(5):347-53. PubMed ID: 3908352
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fenfluramine in Prader-Willi syndrome: a double blind, placebo controlled trial.
    Selikowitz M; Sunman J; Pendergast A; Wright S
    Arch Dis Child; 1990 Jan; 65(1):112-4. PubMed ID: 2405783
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Food intake in Prader-Willi syndrome and controls with obesity after administration of a benzodiazepine receptor agonist.
    Fieldstone A; Zipf WB; Sarter MF; Berntson GG
    Obes Res; 1998 Jan; 6(1):29-33. PubMed ID: 9526967
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessment of hyperphagia in Prader-Willi syndrome.
    Dykens EM; Maxwell MA; Pantino E; Kossler R; Roof E
    Obesity (Silver Spring); 2007 Jul; 15(7):1816-26. PubMed ID: 17636101
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Opiate antagonists and eating behavior in humans: a review.
    de Zwaan M; Mitchell JE
    J Clin Pharmacol; 1992 Dec; 32(12):1060-72. PubMed ID: 1487543
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.